Author:
Tian Tao,Guo Tongqi,Zhen Wei,Zou Jianjun,Li Fuyong
Abstract
AbstractBased on their histological appearance, gliomas are a very common primary tumor type of the brain and are classified into grades, Grade I to Grade IV, of the World Health Organization. Treatment failure is due to the cancer stem cells (CSC) phenotype maintenance and self-renewal. BET degraders such as ZBC260 represents a novel class of BET inhibitors that act by inducing BET proteins degradation. This study explores the mode of action and effects of ZBC260 in vivo and in vitro against glioma. By inhibiting cell proliferation and inducting cell cycle arrest, the fact that glioma cell lines show sensitivity to ZBC260. Notably, ZBC260 targeted glioma without side effects in vivo. In addition, the stem cell-like properties of glioma cells were inhibited upon ZBC260 treatment. When the mechanism was examined, our findings indicated that Wnt/β-catenin pathway repression is required for ZBC260-induced stem cell-like properties and tumor growth suppression. In conclusion, the growth of tumors and stem cell-like properties were inhibited by ZBC260 via Wnt/β-catenin repression, which suggests ZBC260 as a potential therapeutic agent for glioma.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference50 articles.
1. Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M. & Simjee, S. U. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac. J. Cancer Prev. 18, 3–9 (2017).
2. Gupta, M. et al. Prognostic factors in elderly patients with high-grade gliomas: a retrospective analysis of 24 cases. J. Neurosci. Rural Pr. 9, 312–316 (2018).
3. Kern, M., Auer, T. A., Picht, T., Misch, M. & Wiener, E. T2 mapping of molecular subtypes of WHO grade II/III gliomas. BMC Neurol. 20, 8 (2020).
4. Liang, J. et al. Prognostic factors of patients with gliomas-an analysis on 335 patients with glioblastoma and other forms of gliomas. BMC Cancer 20, 35 (2020).
5. Hayashi, S., Kitamura, Y., Hirose, Y., Yoshida, K. & Sasaki, H. Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient’s prognosis. J. Neurooncol. 132, 119–126 (2017).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献